REGENTIS BIOMATERIALS LTD.

HERZLIYA, L3 · CIK 0001912966 · Biotech · Private

Hydrogel platform for tissue repair and regeneration

regentis.co.il →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$6.5M
1 Form D · Jun 2026
4 months since last filing
Contracts
—
No federal contracts on record
Patents
12
6 granted · 6 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$6,500,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1586H-CYTE, INC.—$11M
1587REGENERIX LLC——
1588CHEMILY, LLC——
1589REGENTIS BIOMATERIALS LTD.—$6.5M
1590LEXEO Therapeutics LLC——
1591THERANOSTEC INC——
1592KURE. AI, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 9 related persons
  • Susan AlpertDirector
  • Pini Ben-ElazarDirector
  • Efraim Cohen-AraziDirector
  • Jeff DykanDirector
  • Ehud GellerDirector · Executive Officer
  • Ori GonExecutive Officer
  • Arie GordashnikovExecutive Officer
  • Galit ReskeExecutive Officer
  • Keith ValentineDirector

Patents

USPTO · 6 granted of 12

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.